Newly-elected boards of E Merck KG

29 January 2024

E Merck KG, the company through which the Merck family holds around 70% of German pharma and life sciences company Merck KGaA (MRK: DE), today announced the results of its regular board elections held this past weekend.

Johannes Baillou was elected chairman of the Family Board, which represents the Merck family’s entrepreneurial interests. Mr Baillou has 30 years of board experience at E Merck. First elected to the Family Board in 1994, he became vice chairman of the Board of Partners in 2009 and chairman in 2014. That year, he was also elected vice chairman of the Family Board and Executive Board of E. Merck KG.

Mr Baillou succeeds D Frank Stangenberg-Haverkamp, with whom he has worked side by side for 10 years and who has reached the mandatory retirement age. He had been chairman of the Family Board and Executive Board of E. Merck KG since 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK